Skip to main content
Top
Published in: Obesity Surgery 1/2017

01-01-2017 | Original Contributions

TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation

Authors: Poupak Fallahi, Silvia Martina Ferrari, Stefania Camastra, Ugo Politti, Ilaria Ruffilli, Roberto Vita, Giuseppe Navarra, Salvatore Benvenga, Alessandro Antonelli

Published in: Obesity Surgery | Issue 1/2017

Login to get access

Abstract

Objective

Drug malabsorption is one of the potential troubles after bariatric surgery. Evidence for diminished levothyroxine (L-T4) absorption has been reported in patients after bariatric surgery.

Methods

This study reports 17 cases of hypothyroid patients [who were well replaced with thyroxine tablets (for >1 year) to euthyroid thyrotropin (TSH) levels before surgery (13 Roux-en-Y gastric bypasses (RYGB); 4 biliary pancreatic diversions (BPD))]. From 3 to 8 months after surgery, these patients had elevated TSH levels. Patients were then switched from oral tablets to a liquid L-T4 formulation (with the same dosage, 30 min before breakfast).

Results

Two–three months after the switch, TSH was significantly reduced both in patients treated with RYGB, as in those treated with BPD, while FT4 and FT3 levels were not significantly changed (RYGB group, TSH μIU/mL: 7.58 ± 3.07 vs 3.808 ± 1.83, P < 0.001; BPD group, TSH μIU/mL: 8.82 ± 2.76 vs 3.12 ± 1.33, P < 0.01).

Conclusions

These results first show that liquid L-T4 could prevent the problem of malabsorption in patients with BPD and confirm those of previous studies in patients submitted to RYGB, suggesting that the L-T4 oral liquid formulation could circumvent malabsorption after bariatric surgery.
Literature
1.
go back to reference Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19(12):1605–11. PMID: 19885707.CrossRefPubMed Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19(12):1605–11. PMID: 19885707.CrossRefPubMed
2.
go back to reference Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36. PMID: 23338049.CrossRefPubMed Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36. PMID: 23338049.CrossRefPubMed
3.
go back to reference Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11(8):465–77. PMID: 26055046.CrossRefPubMed Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11(8):465–77. PMID: 26055046.CrossRefPubMed
4.
go back to reference Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016. PMID: 26868660. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016. PMID: 26868660.
5.
go back to reference Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care. 2005;28(2):481–4. PMID: 15677821.CrossRefPubMed Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care. 2005;28(2):481–4. PMID: 15677821.CrossRefPubMed
6.
go back to reference Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7. PMID: 16990631.CrossRefPubMed Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852–7. PMID: 16990631.CrossRefPubMed
7.
go back to reference Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. PMID: 19493300.CrossRefPubMed Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. PMID: 19493300.CrossRefPubMed
8.
go back to reference Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16(1):73–8. PMID: 16487017.CrossRefPubMed Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16(1):73–8. PMID: 16487017.CrossRefPubMed
9.
go back to reference Moulin de Moraes CM, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15(9):1287–91. PMID: 16259889.CrossRefPubMed Moulin de Moraes CM, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15(9):1287–91. PMID: 16259889.CrossRefPubMed
10.
go back to reference Galofré JC, Pujante P, Abreu C, et al. Relationship between thyroid-stimulating hormone and insulin in euthyroid obese men. Ann Nutr Metab. 2008;53(3–4):188–94. PMID: 19011282.CrossRefPubMed Galofré JC, Pujante P, Abreu C, et al. Relationship between thyroid-stimulating hormone and insulin in euthyroid obese men. Ann Nutr Metab. 2008;53(3–4):188–94. PMID: 19011282.CrossRefPubMed
11.
go back to reference Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am. 2012;96(2):369–83. PMID: 22443981.CrossRefPubMed Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Med Clin North Am. 2012;96(2):369–83. PMID: 22443981.CrossRefPubMed
12.
go back to reference Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am. 2012;96(2):203–21. PMID: 22443971.CrossRefPubMed Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am. 2012;96(2):203–21. PMID: 22443971.CrossRefPubMed
13.
go back to reference Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174–80. PMID: 25461470.CrossRefPubMed Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174–80. PMID: 25461470.CrossRefPubMed
14.
go back to reference Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316(13):764–70. PMID: 3821822.CrossRefPubMed Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316(13):764–70. PMID: 3821822.CrossRefPubMed
15.
go back to reference Eledrisi MS, Szymajda A, Alshanti M, et al. Noncompliance with medical treatment: pseudomalabsorption of levothyroxine. South Med J. 2001;94(8):833–6. PMID: 11549198.CrossRefPubMed Eledrisi MS, Szymajda A, Alshanti M, et al. Noncompliance with medical treatment: pseudomalabsorption of levothyroxine. South Med J. 2001;94(8):833–6. PMID: 11549198.CrossRefPubMed
16.
go back to reference Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105–10. PMID: 18996189, Epub 2008 Nov 1.CrossRefPubMed Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105–10. PMID: 18996189, Epub 2008 Nov 1.CrossRefPubMed
17.
go back to reference Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther. 1995;2(10):814–8. PMID: 11854792.CrossRefPubMed Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther. 1995;2(10):814–8. PMID: 11854792.CrossRefPubMed
18.
go back to reference Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95. PMID: 16641395.CrossRefPubMed Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95. PMID: 16641395.CrossRefPubMed
19.
go back to reference Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119(6):492–502. PMID: 8357116.CrossRefPubMed Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119(6):492–502. PMID: 8357116.CrossRefPubMed
20.
go back to reference Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23(6):781–92. PMID: 19942153.CrossRefPubMed Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23(6):781–92. PMID: 19942153.CrossRefPubMed
21.
go back to reference Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60. PMID: 18474247.CrossRefPubMed Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60. PMID: 18474247.CrossRefPubMed
22.
go back to reference Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab. 2008;93(2):465–9. PMID: 18042648.CrossRefPubMed Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab. 2008;93(2):465–9. PMID: 18042648.CrossRefPubMed
23.
go back to reference Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345–9. PMID: 17669709.CrossRefPubMed Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345–9. PMID: 17669709.CrossRefPubMed
24.
go back to reference Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med. 1979;90(6):941–2. PMID: 443690.CrossRefPubMed Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med. 1979;90(6):941–2. PMID: 443690.CrossRefPubMed
25.
go back to reference Bevan JS, Munro JF. Thyroxine malabsorption following intestinal bypass surgery. Int J Obes. 1986;10(3):245–6. PMID: 3759332.PubMed Bevan JS, Munro JF. Thyroxine malabsorption following intestinal bypass surgery. Int J Obes. 1986;10(3):245–6. PMID: 3759332.PubMed
26.
go back to reference Pirola I, Formenti AM, Gandossi E, et al. Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg. 2013;23(9):1493–6. PMID: 23824980.CrossRefPubMedPubMedCentral Pirola I, Formenti AM, Gandossi E, et al. Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes Surg. 2013;23(9):1493–6. PMID: 23824980.CrossRefPubMedPubMedCentral
27.
go back to reference Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54(8):2093–102. PMID: 21614570.CrossRefPubMed Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54(8):2093–102. PMID: 21614570.CrossRefPubMed
28.
go back to reference Scopinaro N, Gianetta E, Civalleri D, et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg. 1979;66(9):618–20. PMID: 497645.CrossRefPubMed Scopinaro N, Gianetta E, Civalleri D, et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg. 1979;66(9):618–20. PMID: 497645.CrossRefPubMed
29.
30.
go back to reference Carswell KA, Belgaumkar AP, Amiel SA, Patel AG. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2015. PMID: 26210195 Carswell KA, Belgaumkar AP, Amiel SA, Patel AG. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2015. PMID: 26210195
32.
go back to reference Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol. 2009;8:37. PMID: 19619292.CrossRefPubMedPubMedCentral Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol. 2009;8:37. PMID: 19619292.CrossRefPubMedPubMedCentral
33.
go back to reference Saraceno G, Vita R, Trimarchi F, et al. A liquid formulation of L- thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. Presented at European Society of Endocrinology ICE/ECE 2012 May Florence, Italy. Endocr Abstr. 2012;29:P1626. Saraceno G, Vita R, Trimarchi F, et al. A liquid formulation of L- thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. Presented at European Society of Endocrinology ICE/ECE 2012 May Florence, Italy. Endocr Abstr. 2012;29:P1626.
34.
go back to reference Vita R, Fallahi P, Antonelli A, et al. The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014;11(7):1103–11. PMID: 24896369.CrossRefPubMed Vita R, Fallahi P, Antonelli A, et al. The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014;11(7):1103–11. PMID: 24896369.CrossRefPubMed
35.
go back to reference Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41(9):661–80. PMID: 12126458.CrossRefPubMed Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41(9):661–80. PMID: 12126458.CrossRefPubMed
Metadata
Title
TSH Normalization in Bariatric Surgery Patients After the Switch from l-Thyroxine in Tablet to an Oral Liquid Formulation
Authors
Poupak Fallahi
Silvia Martina Ferrari
Stefania Camastra
Ugo Politti
Ilaria Ruffilli
Roberto Vita
Giuseppe Navarra
Salvatore Benvenga
Alessandro Antonelli
Publication date
01-01-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 1/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2247-4

Other articles of this Issue 1/2017

Obesity Surgery 1/2017 Go to the issue